Spots Global Cancer Trial Database for dose finding
Every month we try and update this database with for dose finding cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | NCT04739813 | Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom... | obinutuzumab prednisone Revlimid Polatuzumab ibrutinib venetoclax | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3 | NCT01634503 | Cervical Intrae... | GX-188E adminis... | 20 Years - 50 Years | Genexine, Inc. | |
| Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors | NCT00940498 | Neoplasms | PF-05212384 (al... | 18 Years - 99 Years | Pfizer | |
| Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer | NCT01048320 | Advanced Pancre... | Gemcitabine Oxaliplatin Imatinib | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | NCT04739813 | Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom... | obinutuzumab prednisone Revlimid Polatuzumab ibrutinib venetoclax | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Safety of CHIR-258 (TKI258) in Advanced Solid Tumors | NCT01270906 | Neoplasms Cancer Tumors | CHIR-258 (TKI25... | 18 Years - | Novartis | |
| Dose Escalating Study for Amphinex-based PCI of Bleomycin. | NCT01872923 | Cutaneous or Su... | Amphinex Bleomycin Laser | 18 Years - | PCI Biotech AS | |
| A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT04860466 | Lymphoma, Non-H... | CC-96673 | 18 Years - | Celgene | |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | NCT05371054 | Lymphoma Non-Hodgkin Lym... NHL Hematologic Mal... Lymphoid Malign... | Vysis LSI MYC B... venetoclax VIP152 prednisone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3 | NCT01634503 | Cervical Intrae... | GX-188E adminis... | 20 Years - 50 Years | Genexine, Inc. | |
| A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children | NCT00213239 | Hematologic Dis... Neoplasms | Remifentanil Remifentanil | 4 Years - 11 Years | The Hospital for Sick Children | |
| A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children | NCT00213239 | Hematologic Dis... Neoplasms | Remifentanil Remifentanil | 4 Years - 11 Years | The Hospital for Sick Children | |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | NCT05371054 | Lymphoma Non-Hodgkin Lym... NHL Hematologic Mal... Lymphoid Malign... | Vysis LSI MYC B... venetoclax VIP152 prednisone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours | NCT01163903 | Advanced Solid ... | pantoprazole so... doxorubicin hyd... | 18 Years - | University Health Network, Toronto |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
